Former Aetna CEO Ron Williams weighs in on what changes could be ahead for the Affordable Care Act and consumers. » Read More
By: Dan Mangan
UnitedHealth denies allegations it gamed the nation's Medicare system for hundreds of millions of dollars. » Read More
By: Elizabeth Gurdus
The burdens of repealing and replacing Obamacare will fall on consumers, Mark Cuban tells CNBC. » Read More
By: Bertha Coombs
House Speaker Paul Ryan said they plan to introduce legislation as early as next Tuesday. » Read More
U.S. government warnings that a quarter of Puerto Ricans could be infected with Zika are overblown, Clarisa Jimenez said.
The insurer had been asking for average rate hikes of more than 17% before its decision to exit.
Companies are also paying higher premiums, and having workers pay more in premiums, executives said.
Aetna's decision to exit many Obamacare markets echoes similar moves by two other big insurers.
The hunt for yield has increased valuations for pharma stocks above their biotech counterparts, a rare feat that may present a buying opportunity.
Aetna says it will offer individual Affordable Care Act exchange plans in just four states, down from 15 this year, to reduce its losses.
This pediatrician can't believe that Congress would take a seven-week vacation at the height of mosquito season without approving Zika funding first.
Aetna dropping Obamacare is another bad omen for the program, says consultant Robert Laszewski. But we can still make it work.
Shares of Valeant Pharmaceuticals rose more than 6 percent after a Mizuho Securities analyst who had been bearish on the stock upgraded it.
CXRX shares plunged more than 27 percent after it posted quarterly earnings that missed estimates and replaced their CFO.
You'll be paying even more for health insurance at work in 2017. Get the lowdown on a plan that can help you save.
Valeant Pharmaceuticals shares fell more than 9 percent in pre-market trading after The Wall Street Journal reported the company is under federal investigation.
Endo International shares surged after it posted second-quarter earnings that exceeded analysts expectations and appointed new management.
Valeant Pharmaceuticals reported quarterly earnings and revenue that fell short of analysts' expectations on Tuesday.
A record-setting $5.55 million settlement this month came after two settlements totaling close to that amount in July.
The U.S. Food and Drug Administration issued its final word on a trial for the genetically-modified Oxitec mosquito in Florida.
Shares of Bristol-Myers Squibb briefly fell more than 17 percent in opening trade Friday after its cancer drug failed to meet targets in a late-stage study.
The opioid drug crisis could become a big hurdle for states wooing businesses by touting their great quality of life and workforce.
Illinois-based Advocate Health Care Network will pay $5.55 million to federal regulators.
Medicare open enrollment is coming up. Find out how you can save on coverage and out-of-pocket costs.
Get the best of CNBC in your inbox